Black Diamond Therapeutics, Inc.(BDTX)Stock Analysis

BDTX Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Black Diamond Therapeutics, Inc. (BDTX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores BDTX at 57.5/100 on a 32-signal composite quality model, placing it at rank #1,036 of 2,879 stocks — the top half of the AI-ranked universe. BDTX scores in the top quartile across balance sheet strength (96.5), profitability (93.5), free cash flow (89.3). Areas of concern include institutional flow (8.9) and revenue scale (13.9), which score below median versus the broader universe. Shareholder dilution risk is elevated at 17.4/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Black Diamond Therapeutics, Inc. reports net income of $-9.0M, free cash flow of $-10.2M. Top institutional holders of BDTX by reported 13-F value include NEA Management Company,, RENAISSANCE TECHNOLOGIES, DIMENSIONAL FUND ADVISORS, based on the most recent SEC filings. BDTX trades on the Nasdaq exchange and files with the SEC under CIK 1701541. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BDTX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Black Diamond Therapeutics, Inc. directly from SEC EDGAR.